Teva Pharmaceutical Industries Financial Results
Teva Pharmaceutical Industries reported Q3 2026 revenues of $4.4 billion, a 2% decrease year-over-year due to competition for its generic Revlimid, offset by 33% growth in its innovative brand portfolio. The company raised its full-year 2026 revenue outlook for key brands AUSTEDO, AJOVY, and UZEDY following strong quarterly performance and gross margin expansion.
- Term
- Q3 2026
“Teva’s Pivot to Growth strategy is delivering strong results, as evidenced by the 33% growth across our key innovative brands and the substantial expansion of our non-GAAP gross profit margin to its highest level in a decade. We are strengthening our neuroscience leadership with the launch of WELTRUZA™ and the strategic addition of BXCL-501, while our biosimilars business is set to achieve its 2027 revenue goal a year ahead of schedule.”
Richard Francis, Teva's President and CEO